Yahoo Finance • 15 days ago
Postpartum depression is a leading cause of maternal mortality in Europe1-2, and is one of the most common medical conditions associated with pregnancy3-5; up to 20% of women experience postpartum depressive symptoms6-11The approval of thi... Full story
Yahoo Finance • 25 days ago
Investors looking for growth chances at fair prices often consider methods that find companies with good expansion possibilities without high costs. The Affordable Growth method centers on stocks showing strong growth paths, good profitabi... Full story
Yahoo Finance • last month
ROCKVILLE, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, a... Full story
Yahoo Finance • 2 months ago
Third Avenue Management, an investment management company based in New York City, released its “Third Avenue Small-Cap Value Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. During the quarter, the fu... Full story
Yahoo Finance • 2 months ago
Investing.com - Stifel raised its price target on Supernus Pharmaceuticals (NASDAQ:SUPN) to $43.00 from $38.00 on Wednesday, while maintaining a Hold rating on the stock. According to InvestingPro data, the stock is currently trading near... Full story
Yahoo Finance • 2 months ago
Earnings Call Insights: Supernus Pharmaceuticals (SUPN) Q2 2025 MANAGEMENT VIEW * CEO Jack A. Khattar stated that "Supernus continues to execute well against its growth plan and had a strong and very active second quarter." He highligh... Full story
Yahoo Finance • 2 months ago
Supernus Pharmaceuticals reported its Q2 2025 earnings, revealing a mixed financial performance. The company achieved a revenue of $165 million, surpassing the forecast of $154.3 million by 7.26%. However, its earnings per share (EPS) fell... Full story
Yahoo Finance • 2 months ago
Net sales of Qelbree® increased 31% in the second quarter of 2025, compared to the same period in 2024. Net sales of Qelbree of $77.6 million and $142.3 million in the second quarter and first six months of 2025, respectively.Net sales of... Full story
Yahoo Finance • 2 months ago
ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) (“Supernus”) today announced that it has successfully completed its previously announced acquisition of Sage Therapeutics, Inc. (Nasdaq: SAGE... Full story
Yahoo Finance • 2 months ago
[Close up image of wooden cubes with alphabet Q2 on office desk.] mohd izzuan Biogen (NASDAQ:BIIB [https://seekingalpha.com/symbol/BIIB]) traded ~8% higher in the premarket on Thursday after the company posted better-than-expected financi... Full story
Yahoo Finance • 2 months ago
Over the last 7 days, the United States market has remained flat, yet it has experienced a notable increase of 17% over the past year with earnings forecasted to grow by 15% annually. In this environment, identifying stocks that are tradin... Full story
Yahoo Finance • 2 months ago
Key Insights Using the 2 Stage Free Cash Flow to Equity, Supernus Pharmaceuticals fair value estimate is US$66.72 Current share price of US$33.45 suggests Supernus Pharmaceuticals is potentially 50% undervalued Analyst price target for SU... Full story
Yahoo Finance • 2 months ago
ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitru... Full story
Yahoo Finance • 2 months ago
ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, t... Full story
Yahoo Finance • 3 months ago
Investing.com - Scotiabank (TSX:BNS) downgraded Sage Therapeutics (NASDAQ:SAGE) from Sector Outperform to Sector Perform on Tuesday, while lowering its price target to $9.20 from $12.00. The stock, currently trading at $9.17, has shown r... Full story
Yahoo Finance • 3 months ago
Health care stocks advanced late Tuesday afternoon, with the NYSE Health Care Index and the Health C PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 4 months ago
TD Cowen lowered its price target on Sage Therapeutics (NASDAQ:SAGE) stock to $8.50 from $9.00 on Monday, while maintaining a Hold rating on the biopharmaceutical company. The stock, currently trading at $9.1, has shown remarkable momentum... Full story
Yahoo Finance • 4 months ago
Truist Securities raised its price target on Sage Therapeutics (NASDAQ:SAGE) to $9.00 from $8.00 on Tuesday, while maintaining a Hold rating on the stock. The company’s shares, currently trading at $9.07, have surged nearly 30% in the past... Full story
Yahoo Finance • 4 months ago
Supernus Pharmaceuticals (NASDAQ:SUPN), currently valued at $2.03 billion and maintaining impressive gross margins of 88.42%, is acquiring Sage Therapeutics in an all-cash transaction valued at up to $795 million, according to a research n... Full story
Yahoo Finance • 4 months ago
Stock market futures are up slightly. Enthusiasm has been tempered by geopolitical risks and uncertainty ahead of Wednesday’s Federal Reserve decision. The Fed is widely expected to hold rates steady, but investors are laser-focused on Cha... Full story